US FDA approves melt-in-your-mouth metoclopramide, Wilmington's first product
This article was originally published in Scrip
Executive Summary
The US FDA has given the green light to Wilmington Pharmaceuticals/Salix Pharmaceutical's Metozolv ODT, an orally disintegrating formulation of metoclopramide HCl, for the treatment of diabetic gastroparesis and short-term gastroesophageal reflux disease (GERD).